Significance of interleukin-6 (IL-6) in breast cancer (review)

被引:316
作者
Knuepfer, Heike [1 ]
Preiss, Rainer [1 ]
机构
[1] Univ Leipzig, Inst Clin Pharmacol, D-04107 Leipzig, Germany
关键词
breast cancer; interleukin-6; prognostic factor;
D O I
10.1007/s10549-006-9328-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cytokines are factors that are known to have both tumor-promoting and inhibitory effects on breast cancer growth depending presumably on their relative concentrations and the presence of other modulating factors. Different cytokines play an important role in controlling the immune system. Interleukin-6 (IL-6) is a pleiotropic cytokine with obviously tumor-promoting and tumor-inhibitory effects. Here, we review the role of IL-6 in in vitro experiments of breast tumor cells, in breast tumor tissues (BTs) and assess its potential as a prognostic indicator in breast cancer patients. A literature search was conducted using PubMed, restricted to articles published in English language. In summary, results regarding the effect of IL-6 on breast tumor cells and on BTs are not unique indicating both tumor-promoting and inhibitory effects of IL-6. Concerning patients' serum IL-6 levels, data are surprisingly unique showing IL-6 to be a negative prognosticator in breast tumor patients.
引用
收藏
页码:129 / 135
页数:7
相关论文
共 54 条
  • [1] The immune response to breast cancer, and the case for DC immunotherapy
    Allan, CP
    Turtle, CJ
    Mainwaring, PN
    Pyke, C
    Hart, DNJ
    [J]. CYTOTHERAPY, 2004, 6 (02) : 154 - 163
  • [2] Cytokines facilitate chemotactic motility of breast carcinoma cells
    Arihiro K.
    Oda H.
    Kaneko M.
    Inai K.
    [J]. Breast Cancer, 2000, 7 (3) : 221 - 230
  • [3] The effects of IL-6 on cell adhesion and E-cadherin expression in breast cancer
    Asgeirsson, KS
    Olafsdottir, K
    Jonasson, JG
    Ogmundsdottir, HM
    [J]. CYTOKINE, 1998, 10 (09) : 720 - 728
  • [4] Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients
    Bachelot, T
    Ray-Coquard, I
    Menetrier-Caux, C
    Rastkha, M
    Duc, A
    Blay, JY
    [J]. BRITISH JOURNAL OF CANCER, 2003, 88 (11) : 1721 - 1726
  • [5] NORMAL BREAST EPITHELIAL-CELLS PRODUCE INTERLEUKIN-6 AND INTERLEUKIN-8 TOGETHER WITH TUMOR-NECROSIS-FACTOR - DEFECTIVE IL6 EXPRESSION IN MAMMARY-CARCINOMA
    BASOLO, F
    CONALDI, PG
    FIORE, L
    CALVO, S
    TONIOLO, A
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1993, 55 (06) : 926 - 930
  • [6] Inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactions
    Ben-Baruch, A
    [J]. BREAST CANCER RESEARCH, 2003, 5 (01) : 31 - 36
  • [7] Tumour necrosis factor and PI3-kinase control oestrogen receptor alpha protein level and its transrepression function
    Bhat-Nakshatri, P
    Campbell, RA
    Patel, NM
    Newton, TR
    King, AJ
    Marshall, MS
    Ali, S
    Nakshatri, H
    [J]. BRITISH JOURNAL OF CANCER, 2004, 90 (04) : 853 - 859
  • [8] Tumour necrosis factor-alpha, interleukin-6, and fasting serum insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapy
    Bozcuk, H
    Uslu, G
    Samur, M
    Yildiz, M
    Özben, T
    Özdogan, M
    Artaç, M
    Altunbas, H
    Akan, I
    Savas, B
    [J]. CYTOKINE, 2004, 27 (2-3) : 58 - 65
  • [9] Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation
    Brocke-Heidrich, K
    Kretzschmar, AK
    Pfeifer, G
    Henze, C
    Löffler, D
    Koczan, D
    Thiesen, HJ
    Burger, R
    Gramatzki, M
    Horn, F
    [J]. BLOOD, 2004, 103 (01) : 242 - 251
  • [10] Chiu JJ, 1996, CLIN CANCER RES, V2, P215